EUVIMEDEUVIMED entdecken
Open Access

Evaluation of Enoxaparin Dosing in Infants Greater Than 2 to 6 Months of Age, a Pre and Post Quasi Experiment

Colleen Jamie Djordjevich, Colleen Cloyd, Emma Wysocki, Vedat O Yildiz, Vilmarie Rodriguez

The Journal of Pediatric Pharmacology and Therapeutics · 2026-08 · 31 (4) · 516-522

DOI: 10.5863/jppt-25-00077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pediatric Pharmacology and Therapeutics, 2026-08. Verfasst von Colleen Jamie Djordjevich und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy (CJD, CC), Nationwide Children's Hospital, Columbus, OH. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Enoxaparin is regularly used to treat thromboembolism in children. Numerous retrospective studies suggest that infants and young children require higher enoxaparin doses to achieve therapeutic anti-factor Xa (AXA) concentration of 0.5 to 1.0 units/mL compared with adults. METHODS This is a retrospective analysis of pre- and post-implementation of an increased initial dose of enoxaparin (1.2 mg/kg every 12 hours) for infants between 2 and 6 months of age. The objective is to compare the number of dose adjustments needed to achieve therapeutic AXA. RESULTS A total of 64 patients were included 30 pre- and 34 post-guideline groups. In both the pre- and post-guideline dosing groups the number of dose adjustments required to achieve therapeutic AXA when adjusted per the ACCP guidelines was a median of 1 (p = 0.35). However, the first initial AXA was 0.3 units/mL in the pre-guideline group and 0.48 units/mL in the post-guideline group (p = 0.07). There were no documented instances of major bleeding events in either group. CONCLUSION The results support the recommendation of an increased enoxaparin starting dose for therapeutic anticoagulation in the described patient population at the study site. A large prospective study is needed to determine specific dose recommendations that will achieve therapeutic AXA concentrations for the majority of infants and children of all ages.

Schlagwörter

Stichwörter der Autor:innen

enoxaparininfantlow molecular weight heparinpediatricthromboembolism

Autor:innen und Institutionen

  • Department of Pharmacy (CJD, CC), Nationwide Children's Hospital, Columbus, OH.
  • Department of Pharmacy (EW), Geisinger Medical Center, Danville, PA.
  • Center for Biostatistics, Department of Biomedical Informatics (VOY), College of Medicine, The Ohio State University.
  • Division of Hematology/Oncology/Blood and Marrow Transplantation (VR), Nationwide Children's Hospital, Columbus, OH.

Zitieren

APA

Djordjevich, C. J., Cloyd, C., Wysocki, E., Yildiz, V. O., & Rodriguez, V. (2026). Evaluation of Enoxaparin Dosing in Infants Greater Than 2 to 6 Months of Age, a Pre and Post Quasi Experiment. The Journal of Pediatric Pharmacology and Therapeutics, 31(4), 516-522. https://doi.org/10.5863/jppt-25-00077

Vancouver

Djordjevich CJ, Cloyd C, Wysocki E, Yildiz VO, Rodriguez V. Evaluation of Enoxaparin Dosing in Infants Greater Than 2 to 6 Months of Age, a Pre and Post Quasi Experiment. The Journal of Pediatric Pharmacology and Therapeutics. 2026;31(4):516-522. doi:10.5863/jppt-25-00077

BibTeX
@article{Djordjevich2026,
  author = {Djordjevich, Colleen Jamie and Cloyd, Colleen and Wysocki, Emma and Yildiz, Vedat O and Rodriguez, Vilmarie},
  title = {Evaluation of Enoxaparin Dosing in Infants Greater Than 2 to 6 Months of Age, a Pre and Post Quasi Experiment},
  journal = {The Journal of Pediatric Pharmacology and Therapeutics},
  year = {2026},
  volume = {31},
  number = {4},
  pages = {516--522},
  doi = {10.5863/jppt-25-00077}
}
Kostenlos starten →